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A trial-based economic evaluation of 2 nurse-led
disease management programs in heart failure
Douwe Postmus, PhD, a,e Anees A. Abdul Pari, MD, a,b,e Tiny Jaarsma, PhD, c Marie Louise Luttik, PhD, d
Dirk J. van Veldhuisen, PhD, d Hans L. Hillege, PhD, a,d and Erik Buskens, PhD a Groningen, The Netherlands;
Oxford, United Kingdom; and Norrköping, SwedenBackground Although previously conducted meta-analyses suggest that nurse-led disease management programs in
heart failure (HF) can improve patient outcomes, uncertainty regarding the cost-effectiveness of such programs remains.
Methods To compare the relative merits of 2 variants of a nurse-led disease management program (basic or intensive
support by a nurse specialized in the management of patients with HF) against care as usual (routine follow-up by a
cardiologist), a trial-based economic evaluation was conducted alongside the COACH study.
Results In terms of costs per life-year, basic support was found to dominate care as usual, whereas the incremental cost-
effectiveness ratio between intensive support and basic support was found to be equal to €532,762 per life-year; in terms of
costs per quality-adjusted life-year (QALY), basic support was found to dominate both care as usual and intensive support. An
assessment of the uncertainty surrounding these findings showed that, at a threshold value of €20,000 per life-year/€20,000
per QALY, basic support was found to have a probability of 69/62% of being optimal against 17/30% and 14/8% for care
as usual and intensive support, respectively. The results of our subgroup analysis suggest that a stratified approach based on
offering basic support to patients with mild to moderate HF and intensive support to patients with severe HF would be optimal if
the willingness-to-pay threshold exceeds €45,345 per life-year/€59,289 per QALY.
Conclusions Although the differences in costs and effects among the 3 study groups were not statistically significant,
from a decision-making perspective, basic support still had a relatively large probability of generating the highest health
outcomes at the lowest costs. Our results also substantiated that a stratified approach based on offering basic support to
patients with mild to moderate HF and intensive support to patients with severe HF could further improve health outcomes at
slightly higher costs. (Am Heart J 2011;162:1096-104.)With readmission rates varying between 13% and 50%
over a period ranging from 15 days to 6 months,
respectively, recurrent hospitalization in patients with
heart failure (HF) poses an increasing demand on the
scarce health care resources.1 In addition, mortality
after hospitalization for acute HF reaches up to 18.7%
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These alarming event rates provide ample justification
for identifying opportunities to improve quality of care
and treatment compliance and to lower the rates of
hospital readmission.
Because of an increasing demand on health care services,
provision of patient care by specialized nurses is on the rise
in several Western nations.3,4 The results of previously
published meta-analyses suggest that nurse-led disease
management programs can indeed improve clinical
outcome and quality of life in patients with HF.5,6
However, until now, only few articles have addressed
the important question of whether such programs can
produce these favorable effects in an affordable manner.7-9
The aim of the present study was to assess whether the
nurse-led disease management programs from the
COACH study were cost-effective.10 To our knowledge,
no cost-effectiveness analysis has yet been conducted
alongside such a large-scale, multicenter trial in which
different levels of intensity for nurse-led management of
patients with HF were compared against routine follow-
up visits to a cardiologist.
Figure 1
Follow-up visits within each of the 3 study groups.
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Randomized controlled trial
The COACH study was a multicenter, randomized controlled
trial in which 1,023 patients from 17 hospitals were enrolled
during a hospitalization because of HF.10 Patients were
randomly assigned to either the care-as-usual group (routine
follow-up by a cardiologist) or to 1 of the 2 intervention groups
with additional basic or intensive support by a nurse trained in
the management of patients with HF (see Figure 1 for a detailed
overview). All patients were ≥18 years and had evidence of
structural cardiac dysfunction (both patients with impaired and
preserved left ventricle ejection fraction could participate). The
major reasons for exclusion were concomitant enrollment in
another trial, ongoing assessment for heart transplantation,
recent history of an invasive procedure or cardiac surgery
within the last 6 months, or plan of undergoing such a
procedure within the next 3 months.
The first primary end point was a composite of HF read-
mission or death from any cause. A hospitalization for HF was
defined as an unplanned overnight stay in a hospital due to
progression of HF or directly related to HF. The second primary
end point was the number of days lost because of death or HF
readmission. The secondary end points were the 2 individual
components of the combined end point: readmission for HF or
death from any cause. Data on readmission and mortality were
collected from the patient's medical record and by interviews
with the patient during follow-up. The reason for readmission,
the cause of death, and the date of the event were adjudicated
by a central end point committee. The total follow-up time of the
trial was 18 months.Costs
The economic evaluation was conducted from a health
services' perspective, meaning that only direct costs within
the health care sector were included. Indirect costs, such as
productivity losses, were considered to be less relevant because
most patients had retired. In particular, the following 4 cost
categories were identified:
1. the cost of the intervention;
2. the cost of cardiovascular- and non–cardiovascular-related
short-stay hospital admissions (ie, hospital admissions that
do not require an overnight stay in the hospital);
3. the cost of cardiovascular- and non–cardiovascular-related
hospitalization; and
4. thecostsofallrecordedHF-relateddiagnosticprocedures(ie,
echocardiography, coronary angiography, and bike tests).
The major groups of HF-related medication used during the
trial were angiotensin-converting enzyme inhibitors, β-blockers,
angiotensin receptor blockers, and diuretics. The costs of these
medicines were not included in the analysis because of their
low-average costs, making them unlikely to have a significant
impact on the differences in costs between the study groups.
Moreover, the nurse-led intervention was primarily aimed at
education and counseling and not at drug titration. The costs of
the medical procedures conducted during hospitalization or
short-stay hospital admission, such as percutaneous coronary
intervention or implantation of a pacemaker, would be relevant
to consider, but these procedures were not rigorously
recorded during the COACH study. These costs could,
therefore, not be taken into account in the analysis.
Table I. Overview of the various resources per cost category and
their unit costs
Cost category Measurement unit Unit cost (€)
Intervention
Inpatient hospital visits Per visit 29
Home visits Per visit 59
Outpatient visits Per visit 110
Telephone contacts Per call 5
Multidisciplinary advice Per visit 31
Hospitalization
Cardiovascular related Per day 769
Non–cardiovascular related Per day 522
Short-stay admission Per admission 251
HF-related diagnostics Per procedure various
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December 2011The cost of cardiovascular-related hospitalization is the main
driver in the economic evaluation of disease management
programs in HF.11,12 In our study, we therefore used micro
costing13 to determine the real cost per overnight stay in a
coronary care unit (CCU) and a general (cardiac) ward.
Although the distribution of stay over different wards during
hospitalization is important to consider from a cost perspective,
it was not recorded during the COACH study. After seeking
expert opinion from experienced cardiologists, we decided to
roughly allocate 30% of a patient's length of stay to a CCU and
70% to a general ward for an admission related to a
cardiovascular disease. For admissions unrelated to cardiovas-
cular causes, the standard unit cost for an overnight stay in a
Dutch general ward was applied.14 The unit costs of an inpatient
visit by the HF nurse, a home visit, and a telephone contact were
estimated by multiplying the HF nurses' average time consump-
tion by their salary costs and raised to a surcharge of 35%
overhead and 10% housing wherever appropriate.14 The unit
costs of an outpatient visit to the HF nurse and/or cardiologist
and a 30-minute session of multidisciplinary advice were
obtained from The Dutch manual for costing.14 This manual
was also used to obtain the unit cost of a short-stay hospital
admission and the unit costs of an echocardiogram, a coronary
angiogram, and a bike test.
Table I provides an overview of the various resources per cost
category and their unit costs. All costs were assessed in Euros
and, wherever required, adjusted to 2009 prices by using a
national consumer price index. Costs were calculated at the
level of individual patients by multiplying the patients' volumes
of resource use as recorded on the case report form by the
obtained unit costs. Differences in resource use among the 3
study groups were assessed by using a Kruskal-Wallis rank test.
Health outcomes
The effectiveness of care as usual, basic support, and intensive
support was assessed in terms of survival and quality-adjusted
survival. Mean survival time for each of the 3 study groups was
estimated by integration of the area under the Kaplan-Meier
survival curves, and differences among the groups were tested
for by means of a log-rank test. Mean quality-adjusted survival
time was estimated by using inverse probability weighting.15
The utilities underlying the quality-adjusted survival time
calculations were derived from the patients' SF-36 scores—
which were collected through self-reported questionnaires atbaseline and 1, 6, 12, and 18 months postrandomization—by
using the algorithm developed by Brazier et al.16 Mixed-effect
modeling was used to test whether the average evolution of
utility over time was different among the 3 study groups. Visual
inspection of the mean profiles per treatment group suggested
that the average evolution of utility over time was best described
by means of a quadratic function. The fixed-effects structure
therefore included an intercept, the treatment indicator, time,
time2, and the interactions between the treatment indictor and
the included time components. The most suitable random-
effects structure was determined by means of a series of nested
likelihood ratio tests. This resulted in a random-effects structure
consisting of a random intercept and a random slope for the
linear time effect.
Cost-effectiveness analysis
Base case analysis. To assess the balance between the
costs and effects of the 2 nurse-led disease management
programs and care as usual, we first explored whether any of
the strategies was dominated by another strategy (or a linear
combination of the other strategies) having both lower mean
cost and greater mean (quality adjusted) survival time. Then, we
calculated for each nondominated strategy the incremental cost-
effectiveness ratio (ICER), that is, the ratio of the difference in
mean cost and the difference in mean effect, of this strategy
relative to the next less costly and less effective nondominated
strategy and compared these ICERs against the willingness-to-
pay threshold λ to identify the optimal treatment strategy.
To get insight into the sampling uncertainty associated with
these mean values, simple random sampling with replacement
was conducted to obtain 1,000 bootstrap resamples of equal size
to the original sample. For each bootstrap resample, the
strategies' mean costs and mean (quality adjusted) survival
times were estimated, and the differences among them were
calculated. The resulting sampling distributions of the incre-
mental differences in mean cost and mean (quality adjusted)
survival time were summarized graphically by plotting them on
the cost-effectiveness plane. From a decision-maker's perspec-
tive, the probability that a certain strategy is optimal varies,
depending on what the society is willing to pay per unit of heath
gain. This information was summarized graphically by plotting
for each strategy the probability that it was optimal against λ,
resulting in the strategy's cost-effectiveness acceptability curve
(CEAC).17 For any given value of λ, this probability was
determined by taking the fraction of bootstrap resamples for
which the strategy was found to be optimal.
Subgroup analysis. It has previously been suggested that
intensive support could have been more beneficial if it were
explicitly targeted at patients who are likely to be most
responsive to such a program, such as patients with severe
HF18 or patients without depressive symptoms.19 To explore
whether it would be worthwhile to provide different disease
management strategies to different groups of HF patients, a
subgroup analysis was conducted by performing separate
analyses for patients with severe (New York Heart Association
[NYHA] classes III and IV) and less severe (NYHA classes I and
II) HF.
Sensitivity analysis. Because the distribution of stay over
the different wards during cardiovascular-related hospitalization
was not recorded during the COACH study, we allocated 30% of







(n = 344) P
Intervention
Inpatient hospital visits 0.16 (1.77) 0.41 (1.04) 0.89 (1.83) b.001
Home visits 0 0.03 (0.26) 2.14 (1.58) b.001
Outpatient visits 3.38 (2.07) 6.16 (3.35) 7.46 (4.37) b.001
Telephone contacts 0.14 (0.49) 3.55 (3.96) 9.21 (5.99) b.001
Multidisciplinary advice 0 0 1.28 (1.78) b.001
Days in the hospital
Cardiovascular related 8.44 (17.26) 7.58 (15.36) 8.10 (15.63) .93
Non–cardiovascular related 3.76 (11.01) 4.39 (12.28) 4.96 (13.65) .83
Short-stay admission 0.17 (0.50) 0.18 (0.61) 0.17 (0.48) .75
HF-related diagnostics 1.20 (1.50) 1.10 (1.54) 1.42 (1.99) .22
Values are presented as means (SD).
Table III. Mean cost (SD) per cost category
Mean cost Care as usual Basic support Intensive support P
Intervention 376 (239) 707 (369) 1,055 (516) .002
Hospitalization 8458 (14 951) 8125 (13 940) 8818 (13 811) .69
Short-stay admission 41 (129) 45 (148) 43 (111) .75
HF-related diagnostics 1065 (1049) 1052 (1051) 1249 (1235) .22
Total cost 9693 (15 227) 9616 (14 124) 10 794 (13 958) .30
Postmus et al 1099
American Heart Journal
Volume 162, Number 6a patient's length of stay to a CCU and 70% to a general ward. To
investigate the impact of this assumption on the study results,
we varied the fraction of time that a patient spends in a CCU
from 0% to 60%. We also assessed the consequences of doubling
and halving the unit cost of an outpatient visit to the HF clinic,
the main determinant of the intervention cost. Because the
overall uncertainty in the ICER depends on the combined
variability in these factors, we allowed the 2 parameter values to
vary simultaneously.
This research was performed within the framework of the
Center for Translational Molecular Medicine, project TRIUMPH
(grant 01C-103), and supported by the Dutch Heart Foundation.
The authors are solely responsible for the performed analyses,
the drafting and editing of the manuscript, and its final contents.
Results
Patients
A total of 1,023 patients were randomly assigned to
the 3 study groups. The mean age of the participants
was 71 years, and 62.4% were men. The baseline
demographic and clinical characteristics of the 3 groups
were comparable.10
Resource use and costs
An overview of the resource use per study group is
given in Table II. Although the average consumption of
intervention-related resources was still significantly dif-
ferent among the 3 study groups (P b .001), the
differences between basic and intensive support weresmaller compared with what would be expected based
on the study protocol.10 The corresponding mean costs
per cost category are given in Table III. Total cost were
lowest in the basic support group and highest in the
intensive support group, but the differences among the 3
groups were not statistically significant (P = .30).Health outcomes
Survival. The mean survival time was 456.3 days in
the care-as-usual group, 473.9 days in the basic-support
group, and 474.7 days in the intensive-support group
(Figure 2). The observed differences in survival among
the 3 groups were not statistically significant, with a
P value of .34 from the log-rank test.
Quality-adjusted survival. The mean quality-adjust-
ed survival time was 287.6 days in the care-as-usual group,
296.1 days in the basic-support group, and 294.6 days in
the intensive-support group. The average change in SF-6D
utility scores over time is depicted in Figure 3. The results
of the mixed-effect modeling with treatment, time, time2,
and the interactions between treatment and time and
treatment and time2 (Table IV) showed that the average
increase in quality of life over time was statistically
significant, with P values for the time and time2
components of .005 and .034, respectively. These results
also showed that the differences in quality of life at
baseline as well as the differences in the average
evolution of quality of life over time were not statistically
significant among the 3 study groups.
Figure 3
verage evolution of quality of life (SF-6D scores) over time for the 3
tudy groups.
Figure 2
Kaplan-Meier survival curves for the 3 study groups.
Table IV. Maximum likelihood estimates for the fixed effects in
the linear mixed model for the quality-of-life data (SF-6D scores)
arameter β Coefficient (SE) P
tercept .6029 (0.004) b.001
asic support −.00165 (0.006) .774
tensive support −.00929 (0.006) .106
ime .00304 (0.001) .0052
ime2 −.00013 (0.00006) .0335
ime⁎basic support .00143 (0.002) .342
ime⁎intensive support .00218 (0.002) .150
ime2⁎basic support −.00005 (0.00008) .552
ime2⁎intensive support −.00009 (0.00008) .290
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Base case analysis. Based on the mean values
reported above, we can conclude that, in terms of cost
per life-year, basic support dominated care as usual
because it generated 0.048 additional life-years while
saving €77. When comparing the 2 disease management
programs, intensive support was found to generate
0.0022 additional life-years at an excess cost of €1,178,
yielding an ICER of €532,762 per life-year. In terms of
cost per quality-adjusted life-year (QALY), basic support
was found to dominate both care as usual and intensive
support because it generated 0.023 and 0.004 excess
QALYs while saving €77 and €1,178, respectively.
The results of the bootstrap analysis are presented in
Figure 4. Each point on the cost-effectiveness plane
represents a realization from the sampling distribution of
the differences in mean cost and mean (quality adjusted)
survival time. The lower and upper bounds of the 95%
probability intervals for these differences are shown as
vertical and horizontal dashed line segments, respective-
ly. It can be seen from Figure 4 that there were bootstrap
resamples for which basic support no longer dominated
care as usual or intensive support (in terms of cost per
QALY). The CEACs presented in Figure 5, nevertheless,
suggest that basic support still has a large probability of
being the preferred strategy; at a threshold value of
€20,000 per life-year/€20,00 per QALY, basic support
was found to have a probability of 69/62% of being
optimal against 17/30% and 14/8% for care as usual and
intensive support, respectively.
Subgroup analysis. The results of the subgroup












with less severe HF, basic support was still found to
dominate care and usual (both in terms of cost per life-
year and cost per QALY) and intensive support (in terms
of cost per QALY). In terms of cost per life-year, the ICER
between intensive support and basic support was equal
to €445,660 per life-year. For the patients with severe
HF, basic support was no longer a dominating strategy. In
fact, in terms of cost per QALY, basic support was now
found to be extendedly dominated20 by a linear
combination of care as usual and intensive support,
meaning that it is possible to produce the same health
outcomes at a lower cost by giving a proportion of the
patients care as usual and a proportion as intensive
support. The ICER between intensive support and care as
usual was equal to €59,289 per QALY. In terms of cost
Figure 4
One thousand bootstrap estimates of the differences in mean cost and mean (quality adjusted) survival time between basic support and care as
usual (top), intensive support and care as usual (middle), and intensive support and basic support (bottom).
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Volume 162, Number 6per life-year, the ICERs between basic support and care
as usual and intensive support and basic support were
found to be equal to €25,923 per life-year and €45,345
per life-year, respectively.Sensitivity analysis. Although there were combina-
tions of parameter values for which basic support no
longer dominated care as usual, the ICERs never
exceeded €10,000 per life-year and €14,000 per QALY
Figure 5
The CEACs for the bootstrap analyses of cost per life-year (left) and cost per QALY (right).







survival time (d) ICER (cost/QALY)
Patients with less severe HF
Care as usual 8955 483.3 Reference 307.4 Reference
Basic support 7170 504.2 Dominates care as usual 318.3 Dominates care as usual
Intensive support 9099 505.8 2338 313.3 8915
Patients with severe HF
Care as usual 10 692 427.4 Reference 267.8 Reference
Basic support 11 793 442.9 25 923 273.0 77 335
Intensive support 12 462 448.3 30 933 278.7 59 289
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December 2011(results not shown). For intensive support versus basic
support, we obtained ICERs of €442,958 and €654,930
per life-year for the most optimistic and pessimistic
scenarios, respectively. As far as cost per QALY is
concerned, basic support dominated intensive support
for all considered combinations of the 2 parameter values.Discussion
This article reported the results of an economic
evaluation conducted alongside the COACH study, one
of the largest randomized, controlled trials of nurse-led
disease management programs in HF. Although the
differences in mean cost and mean (quality adjusted)
survival time among the 3 study groups were not
statistically significant, an assessment of the strategies'
joint distributions on these 2 outcome measures,
nevertheless, revealed that basic support had a relatively
large probability of being the preferred strategy; at a
threshold value of €20,000 per life-year/€20,000 per
QALY, basic support was found to have a probability of
69/62% of being optimal against 17/30% and 14/8% forcare as usual and intensive support, respectively. Based
on these results, we can conclude that, from a decision-
making perspective, basic support is clearly the favorable
alternative. Although this conclusion may, at first glance,
seem counterintuitive to some readers, it, in fact, reveals
the limitations of applying the traditional rules of
statistical inference to decision problems. Not only are
trials rarely powered to detect statistically significant
differences in costs or QALYs, but also traditional
significance testing puts the emphasis on minimizing
type I error (the probability of rejecting the null
hypothesis when, in fact, that hypothesis is correct),
whereas from a decision-making perspective, the prob-
ability of making a type II error (the probability of
rejecting the alternative hypothesis when, in fact, that
hypothesis is correct) is equally important.13,21
Although we anticipated that a comprehensive and
intensive care would further decrease the number of
readmissions and improve quality of life, our results
proved otherwise. A possible explanation for this finding
could be that intensive support leads to an increase in the
number of cardiovascular-related hospitalizations
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Volume 162, Number 6because of lower thresholds for admitting patients with
mild to moderate HF. We can therefore not rule out the
possibility that intensive support would have been more
efficient if it were explicitly targeted at patients with
severe HF. The results of our subgroup analysis indeed
suggest that a stratified approach based on offering basic
support to patients with mild to moderate HF and
intensive support to patients with severe HF would be
the preferred strategy if the willingness-to-pay threshold
exceeds €45,345 per life-year/€59,289 per QALY.
A strong point of our study is that the analysis was
based on individual patient data collected at 17 centers
across the Netherlands. Our results therefore provide a
realistic picture of the health benefits that could be
achieved if the proposed disease management programs
were implemented on a nationwide scale. Most of the
previous studies on the (cost) effectiveness of nurse-led
disease management programs in HF, in contrast, lack
such a degree of generalizability because they were
conducted in much more idealized and controlled
settings. For example, in the Dutch context, the DEAL-
HF study has shown a remarkable reduction in all-cause
mortality and rehospitalization.22 However, this study
had a relatively small sample size and was only conducted
at 2 regional centers. Likewise, a similar study was
performed in the US setting, but this study was limited to
inner city areas.7 Finally, based on an expected 50%
reduction in recurrent bed use, Stewart et al9 projected
that implementing a nurse-led disease management
program on a nationwide scale is likely to reduce costs
and improve the efficiency of the health care system. In
light of our results, reductions in recurrent bed use of
such large magnitudes seem not very realistic. Our
findings, nevertheless, suggest that implementing a
nurse-led disease management program with a medium
intensity could still be cost saving.
A limitation of our trial-based economic evaluation is
that the COACH study was not explicitly designed for
performing a cost-effectiveness analysis. As a conse-
quence of this, the recording of medical procedures
was not very rigorous. A detailed listing of all relevant
medical procedures would have increased the internal
validity of our results. However, we did have complete
data regarding the most important cost categories (ie,
the consumption of the intervention-related resources
and the number of hospital readmissions). Hence, the
savings observed in the cost of rehospitalization, the
driving cost category in the economics of HF,9 would
still be of utmost interest to a wider audience. In
addition, although the distribution of stay over the
different wards during cardiovascular-related hospitali-
zation was not recorded during the COACH study, the
results of the sensitivity analysis showed that our
findings are robust to changes in the allocation of the
amount of time that a patient spends in a CCU and a
general ward.To conclude, this article is the first to compare the costs
and effects of 2 different variants of a nurse-led disease
management program in HF. Our results provide a strong
scientific case for a broader implementation of such
programs, provided that the intensity of the program is
tailored to the severity of the disease in individual patients
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